Humanized anti-muc1* antibodies and use of cleavage enzyme
AssigneeMinerva Biotechnologies Corporation
InventorsCynthia Bamdad, Benoit Smagghe, Luke Deary
Life of this patent
Estimating the term…
Abstract
The present application discloses humanized antibodies and antibody like proteins and fragments thereof and use of cleavage enzyme.
Claims62
-97. (canceled)
An immune cell transfected or transduced with a cleavage enzyme for the treatment of cancer.
An immune cell transfected or transduced with both a CAR comprising an antibody fragment, and a cleavage enzyme or catalytically active fragment thereof for the treatment of cancer.
(canceled)
A nucleic acid construct comprising nucleic acid encoding a cleavage enzyme or catalytically active fragment thereof located downstream of an NFAT promoter.
The nucleic acid construct comprising nucleic acid encoding a cleavage enzyme or catalytically active fragment thereof located downstream of at least one NFAT response element.
A method of pre-activating an immune cell transduced or transfected with nucleic acid encoding CAR that is specific for MUC1* and/or MUC1 specific cleavage enzyme by co-culturing the immune cell in vitro on a surface that presents a peptide having the sequence of truncated extracellular domain of MUC1, thus obtaining pre-activated immune cell.
An immune cell transfected or transduced with a plasmid encoding a CAR and a plasmid encoding a non-CAR species that is expressed from an inducible promoter.
Dependencies are inferred from the claim text.